Amarantus to Participate in the Eighth Annual OneMedForum Conference on January 12 - 13, 2015
.Amarantus BioScience Holdings, Inc.
SAN FRANCISCO and GENEVA, Jan. 8, 2015 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (AMBS), a biotechnology company focused on the development of diagnostics in Alzheimer's disease and therapeutic products in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, announced that it will participate in the Eighth Annual OneMedForum on January 12 - 13, 2015, at the Marriott Marquis in San Francisco, CA.
The Company will present an overview of its investigational drug MANF (mesencephalic-astrocyte-derived neurotrophic factor) for the treatment of Retinitis Pigmentosa (RP) and Retinal Artery Occlusion (RAO) and its Phase 2b-ready small molecule drug candidate Eltoprazine for the treatment of Parkinson's disease levodopa-induced dyskinesia (PD LID) and Adult ADHD. The Amarantus management team will also participate in a panel discussion on Brain Health and Neurological Diseases.
MANF Development Program Presentation
Monday, January 12, 2015
4:00 p.m. Pacific Time / 7:00 p.m. Eastern Time
Roman Urfer, Ph.D., Chief Development Officer at NeuroAssets
Brain Health and Neurological Diseases Panel
OK...no substantial evidence of any leaks or whispers but then again a decent day so far. Looking for some inspiration from this evenings work.. sa far so good.
Agree, also it is clear that a long term business focus for AMBS is taking shape. May be based on applications of MANF but not exclusively. With this team, it is no surprise that such a vision has emerged.
Any thoughts on when PR and/or data related to presentations will be released? It looks like AMBS is up after EST markets are closed, each day. Is there an established protocol for such releases? (IE, must be after the event for example?) Looking forward to an active few days.
Is 18M$ already firm or is it in the "planning" stage? What evidence do you have on this? Thx. That would resolve a lot of issues if true of course.
Who knows if this will be the one that triggers the explosion? Truth is, only a few have information on when and how (or if) that will happen . Next weeks planned events suggest news. Kind of like holding a lottery ticket where 5 of your numbers have been called and you are waiting for the power ball to match.
Oh, another truth is, you cannot win if you don't play.
Found this..."In a deal that may lead to the first viable treatment for retinal diseases, Amarantus Bioscience Holdings, Inc., a biotechnology company, has exercised its exclusive right to license intellectual property related to a protein product developed by a researcher at the Miller School of Medicine’s Bascom Palmer Eye Institute.
MANF (Mesencephalic-Astrocyte-derived Neurotrophic Factor) is believed to have broad potential because it is a naturally occurring protein produced by the body to reduce or prevent cell death in response to injury or disease. The license agreement covers its use for retinal diseases, include age-related macular degeneration, glaucoma, inherited retinal disorders (including Retinitis pigmentosa), sporadic retinal disorders, other degenerative retinal disorders and retinal injuries.
“We are quite excited about the possibilities for MANF,” said Rong Wen, M.D., Ph.D., professor of ophthalmology and the Bascom Palmer scientist whose research has demonstrated the efficacy of MANF in experimental models of retinal degeneration. “The next step will be to develop the proper method of delivering it to the back of the eye.”
“With interim toxicology data now in hand, and with multiple data sets forthcoming in the third and fourth quarter for the MANF ophthalmology program focused initially on Retinitis pigmentosa, we believe now is the ideal time to exercise our option and move forward under the auspices of a full license agreement,” said Gerald E. Commissiong, president and CEO of Amarantus. “Research groups around the globe have begun to investigate MANF’s utility across a variety of ophthalmological areas, and this license from one of the world’s preeminent ophthalmological institutes positions Amarantus as the sole commercial outlet for current and future inventions.”
august...that reported BP comment is exactly the kind of stuff we need to have formally expressed in the proper context. AMBS credibility can be enhanced by factor(n) with such news. Results and that kind of claim by the right people at the right time is what we need.thx
Saw a little bit of the same thing yesterday (Schwab vs Yahoo ) big variations.on several stocks..with tangled data...looks like the mulitple systems are having errors.
In a way I think you have a point. We will most likely not continue as we have ...between AMBS and RGIN something has to move...I would say that the choice is either .04 or $1.20...lets see ...just a gut check here after a few years of B.S....we are due.
Schwabb and Yahoo close values are not even close to being same. Believe it or not Yahoo looks correct? Anyone seeing different close numbers that Yahoo?